- Report
- August 2022
- 30 Pages
Global
From €2500EUR$2,750USD£2,140GBP
- Report
- January 2022
- 205 Pages
Global
From €6817EUR$7,500USD£5,837GBP
- Report
- January 2024
- 172 Pages
Global
From €1493EUR$1,643USD£1,278GBP
€1991EUR$2,190USD£1,704GBP
- Report
- September 2021
- 105 Pages
Global
€3090EUR$3,400USD£2,646GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €454EUR$500USD£389GBP
Xyrem is a central nervous system (CNS) drug used to treat narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden episodes of sleep. Xyrem is a brand name for sodium oxybate, a form of gamma-hydroxybutyrate (GHB). It is a sedative-hypnotic drug that works by increasing the amount of gamma-aminobutyric acid (GABA) in the brain, which helps to reduce the symptoms of narcolepsy. Xyrem is a Schedule III controlled substance and is only available through a restricted distribution program.
Xyrem is manufactured by Jazz Pharmaceuticals, a specialty pharmaceutical company based in Ireland. Other companies in the Xyrem market include Teva Pharmaceuticals, which markets a generic version of the drug, and Sunovion Pharmaceuticals, which markets a brand-name version of the drug. Show Less Read more